Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
Int J Mol Sci. 2024 Sep 30;25(19):10540. doi: 10.3390/ijms251910540.
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD), which severely affects the quality of patients' lives. However, the current therapeutic approaches can only postpone its progression to ESRD. It is therefore imperative to develop a novel therapeutic strategy for renal injury in DKD, with the objective of restoring renal function and reversing the process of ESRD. In recent years, the potential of mesenchymal stem cell (MSC) therapy for DKD has garnered increasing attention within the scientific community. Preclinical research on MSC therapy has yielded promising results, and the safety of MSC treatment in vivo has been substantiated in clinical studies. An increasing body of evidence suggests that MSC therapy has significant potential for the treatment of DKD. This article reviews the existing research on MSCs and their derived exosomes in treating DKD and analyzes the underlying mechanism of MSC-based therapy for DKD. Additionally, we discuss the potential of combining MSC therapy with conventional pharmacological treatments, along with the constraints and prospects of MSC therapy for DKD. We hope this review can provide a precise and comprehensive understanding of MSCs for the treatment of DKD.
糖尿病肾病（DKD）是终末期肾病（ESRD）的主要原因，严重影响患者的生活质量。然而，目前的治疗方法只能延缓其向 ESRD 的进展。因此，迫切需要开发一种新的 DKD 肾损伤治疗策略，以恢复肾功能并逆转 ESRD 进程。近年来，间充质干细胞（MSC）治疗 DKD 在科学界引起了越来越多的关注。MSC 治疗的临床前研究取得了有希望的结果，并且体内 MSC 治疗的安全性已在临床研究中得到证实。越来越多的证据表明，MSC 治疗在治疗 DKD 方面具有很大的潜力。本文综述了现有的关于 MSC 及其衍生的外泌体治疗 DKD 的研究，并分析了基于 MSC 的 DKD 治疗的潜在机制。此外，我们还讨论了将 MSC 治疗与传统药物治疗相结合的可能性，以及 MSC 治疗 DKD 的局限性和前景。我们希望这篇综述能够为 MSC 治疗 DKD 提供一个准确而全面的理解。
